Trevena Inc
NASDAQ:TRVN
Trevena Inc
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 43 full-time employees. The company went IPO on 2014-01-31. The firm is focused on developing and commercializing medicines for patients affected by central nervous system (CNS) disorders. The company is developing OLINVYK, a G-protein biased MOR ligand for acute pain in adults. The company is developing TRV027, an angiotensin II type 1 (AT1), receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome (ARDS), and abnormal blood clotting in patients with COVID-19. The company is developing TRV250, a G-protein biased delta-opioid receptor (DOR), is developed for the treatment of acute migraine. The firm is focused on exploring other formulations, such as transmucosal or transdermal administration for breakthrough or chronic pain, respectively. The firm is in the Phase III clinical program for OLINVO with the enrollment of patients in the ATHENA study, a Phase III, open-label, multicenter study.
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 43 full-time employees. The company went IPO on 2014-01-31. The firm is focused on developing and commercializing medicines for patients affected by central nervous system (CNS) disorders. The company is developing OLINVYK, a G-protein biased MOR ligand for acute pain in adults. The company is developing TRV027, an angiotensin II type 1 (AT1), receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome (ARDS), and abnormal blood clotting in patients with COVID-19. The company is developing TRV250, a G-protein biased delta-opioid receptor (DOR), is developed for the treatment of acute migraine. The firm is focused on exploring other formulations, such as transmucosal or transdermal administration for breakthrough or chronic pain, respectively. The firm is in the Phase III clinical program for OLINVO with the enrollment of patients in the ATHENA study, a Phase III, open-label, multicenter study.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
